Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Guggenheim Downgrades Alnylam Pharmaceuticals to Neutral

Guggenheim analyst Debjit Chattopadhyay downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Neutral.
byBenzinga Newsdesk
June 27, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Guggenheim analyst Debjit Chattopadhyay downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0